A detailed history of Check Capital Management Inc transactions in Amgen Inc stock. As of the latest transaction made, Check Capital Management Inc holds 3,795 shares of AMGN stock, worth $998,768. This represents 0.04% of its overall portfolio holdings.

Number of Shares
3,795
Previous 3,720 2.02%
Holding current value
$998,768
Previous $1.16 Million 5.16%
% of portfolio
0.04%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$309.38 - $337.38 $23,203 - $25,303
75 Added 2.02%
3,795 $1.22 Million
Q2 2022

Jul 28, 2022

SELL
$230.71 - $256.74 $11,535 - $12,837
-50 Reduced 1.33%
3,720 $905,000
Q1 2021

May 07, 2021

SELL
$221.91 - $258.6 $9,764 - $11,378
-44 Reduced 1.15%
3,770 $938,000
Q4 2020

Feb 03, 2021

BUY
$216.38 - $257.67 $9,953 - $11,852
46 Added 1.22%
3,814 $877,000
Q3 2020

Nov 06, 2020

SELL
$234.65 - $260.95 $47,399 - $52,711
-202 Reduced 5.09%
3,768 $957,000
Q2 2020

Aug 12, 2020

SELL
$197.81 - $242.74 $1,978 - $2,427
-10 Reduced 0.25%
3,970 $936,000
Q1 2020

May 06, 2020

SELL
$182.24 - $241.7 $92,395 - $122,541
-507 Reduced 11.3%
3,980 $807,000
Q4 2019

Feb 10, 2020

SELL
$189.21 - $243.2 $1,324 - $1,702
-7 Reduced 0.16%
4,487 $1.08 Million
Q3 2019

Nov 06, 2019

SELL
$174.11 - $208.62 $6,616 - $7,927
-38 Reduced 0.84%
4,494 $870,000
Q1 2019

May 06, 2019

SELL
$180.87 - $203.88 $15,916 - $17,941
-88 Reduced 1.9%
4,532 $861,000
Q4 2018

Feb 07, 2019

BUY
$178.4 - $208.25 $274,736 - $320,705
1,540 Added 50.0%
4,620 $899,000
Q3 2017

Nov 13, 2017

SELL
$167.29 - $191.0 $515,253 - $588,280
-3,080 Reduced 50.0%
3,080 $574,000
Q3 2017

Nov 08, 2017

BUY
$167.29 - $191.0 $515,253 - $588,280
3,080 Added 100.0%
6,160 $1.15 Million
Q2 2017

Aug 11, 2017

BUY
N/A
3,080
3,080 $530,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Check Capital Management Inc Portfolio

Follow Check Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Check Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Check Capital Management Inc with notifications on news.